• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Results of OncoGenex phase I/II Custirsen trial published

Results of OncoGenex phase I/II Custirsen trial published

January 6, 2012
CenterWatch Staff

OncoGenex Pharmaceuticals has reported results of a phase I/II study to determine the effectiveness of its investigational compound custirsen in conjunction with a gemcitabine/platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC).

Results published in the January 2012 issue of the Journal of Thoracic Oncology showed the additional treatment of custirsen, designed to block production of tumor cell survival protein clusterin, improved survival rates by three to seven months longer than patients who adhered to only a gemcitabine/platinum-based regimen. The combination treatment produced a median overall survival of 14.1 months, and progression-free survival of 4.3 months. Moreover, the patients who achieved a threshold minimum of serum clusterin (</= 45mcg/mL) had a median survival of 27.1 months.

Additionally, the study determined the toxicity of the combination treatment was not appreciably different from that reported for a gemcitabine/platinum-based regimen on its own.

"The identification and targeting of new therapeutic pathways, such as clusterin inhibition, are required in order to improve outcomes for cancer patients," said Dr. Janessa Laskin, principal investigator on the study and a medical oncologist at the British Columbia Cancer Agency.

The single-arm trial, conducted at 15 sites in North America, consisted of 81 patients with untreated, advanced NSCLC. OncoGenex has entered a collaboration and license agreement for custirsen with Teva Pharmaceutical Industries. The companies are planning a randomized, phase III study of custirsen as a first-line treatment of advanced, unresectable non-small cell lung cancer.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing